{
  "main_header": {
    "sid": 1002854,
    "name": "Vanta Bioscience",
    "stock_name": "Vanta Bioscience",
    "full_name": "Vanta Bioscience Ltd",
    "name_url": "stocks-analysis/vanta-bioscience",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "19.50",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "19.50",
    "mcapval": "14.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540729,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 67,
    "indexname": "",
    "isin": "INE695X01011",
    "curr_date": "Jan 23",
    "curr_time": "",
    "bse_nse_vol": "1.5 k",
    "exc_status": "Active",
    "traded_date": "Jan 23, 2026",
    "traded_date_str": "2026 01 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/vanta-bioscience-1002854-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Vanta Bioscience?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-vanta-bioscience-3703961",
        "imagepath": "",
        "date": "2025-11-15 00:20:07",
        "description": "Answer:\nThe historical performance of Vanta Bioscience has shown significant fluctuations over the years, particularly in net sales and profitability. In March 2025, net sales dropped to 1.96 Cr from 9.72 Cr in March 2024, which was a decrease from 6.28 Cr in March 2023 and 9.69 Cr in March 2022. The total operating income followed a similar trend, declining from 9.72 Cr in March 2024 to 1.96 Cr in March 2025. The company has faced increasing total expenditure, which reached 6.22 Cr in March 2025, compared to 8.41 Cr in March 2024. This led to an operating profit (PBDIT) of -4.15 Cr in March 2025, a stark contrast to the positive 1.42 Cr in March 2024. Profit before tax also worsened, recording -4.11 Cr in March 2025, down from -2.54 Cr in March 2024. Consequently, the profit after tax for March 2025 was -4.77 Cr, worsening from -2.32 Cr in March 2024. The company's earnings per share (EPS) reflected this d..."
      }
    ],
    "total": 17,
    "sid": "1002854",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/vanta-bioscience-1002854"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting - Appointment Of Company Secretary And Compliance Officer",
      "datetime": "30-Jan-2026",
      "details": "Outcome of the Board Meeting - Appointment of Company Secretary and Compliance Officer",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14 2025",
      "datetime": "14-Nov-2025",
      "details": "Outcome of the Board Meeting held on November 14 2025",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Half Year Ended September 30 2025",
      "datetime": "14-Nov-2025",
      "details": "Financial results for the half year ended September 30 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Vanta Bioscience?

2025-11-15 00:20:07

Answer: The historical performance of Vanta Bioscience has shown significant fluctuations over the years, particularly in net sales and profitability. In March 2025, net sales dropped to 1.96 Cr from 9.72 Cr in March 2024, which was a decrease from 6.28 Cr in March 2023 and 9.69 Cr in March 2022. The total operating income followed a similar trend, declining from 9.72 Cr in March 2024 to 1.96 Cr in March 2025. The company has faced increasing total expenditure, which reached 6.22 Cr in March 2025, compared to 8.41 Cr in March 2024. This led to an operating profit (PBDIT) of -4.15 Cr in March 2025, a stark contrast to the positive 1.42 Cr in March 2024. Profit before tax also worsened, recording -4.11 Cr in March 2025, down from -2.54 Cr in March 2024. Consequently, the profit after tax for March 2025 was -4.77 Cr, worsening from -2.32 Cr in March 2024. The company's earnings per share (EPS) reflected this d...

Read More

View All News